In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the first two oral antivirals for the treatment of certain COVID-19 patients. These treatments mark a step forward in the fight against the pandemic, due to their ability to be taken at home, which can reduce the burden on both patients and the health care system. Additional treatments are also under investigation by several other biopharmaceutical companies.
